Navigation Links
Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on North America
Date:9/21/2011

NEW YORK, Sept. 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on North America

http://www.reportlinker.com/p0619261/Global-Markets-for-Contract-Pharmaceutical-Manufacturing-Research-and-Packaging-Focus-on-North-America.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Manufacturing

REPORT HIGHLIGHTS

* The global pharmaceutical contract manufacturing and contract research organizations revenue reached at $196.5 billion in 2010, it will further grow to $217.9 billion in 2011 and is projected to reach at $360.6 billion by 2016, increasing at a compound annual growth rate (CAGR) of 10.6%.

* North American markets' revenue for bulk drugs in contract manufacturing in 2009 was about $8.8 billion and increased to about $9.7 billion in 2010. It is projected to reach $16.6 billion by 2016, for a 5-year CAGR of 9.4%.

* The total market for solid dosage form contract manufacturing in 2010 was valued at about $9.1 billion. This is expected to reach $10 billion by 2011 and forecasted to cross $16.1 billion by the end of 2016 at a CAGR of 10% for the five year period.

INTRODUCTION

STUDY OBJECTIVE

The objective of BCC Research in conducting this study is to provide an overview of the current situation and future capabilities of the global pharmaceutical contract manufacturing, research, and packaging markets. The study provides a global as well as a regionally specific market overview. The report emphasizes the current and future outlook of the pharmaceutical contract manufacturing market, with a comprehensive analysis of the overall pharmaceutical and biotechnology outsourcing industry.

The current report discusses and outlines the current capabilities as well as the needs of the pharmaceutical contract manufacturing, research, and packaging markets. In addition, it discusses company and market strategies to further enhance the market. The report includes the different types of contract manufacturing and, more specifically, the services offered by global contract manufacturers, researchers, and packagers. The report also discusses the methods best used to identify an effective contract manufacturer as well as the advantages of contract manufacturing and outsourcing. The REPORT HIGHLIGHTS the need for project management, provides market forecasts for different aspects of contract manufacturing specific to each region, and examines the role of market leaders in the industry. Regulatory requirements and new developments in the market are also discussed in the report.

The report encompasses the revenues gained from contract manufacturing in each specific market and in each specific region. Sales analysis was performed on specific categories of drugs and dosage forms including API/bulk drugs and solid, liquid, and semisolid dosage forms. Sales analyses were also performed on revenues gained from contract packaging and contract research. The sales figures discussed are for the examined period of 2009 to 2011. Sales figures were also forecast for the following 5-year period from 2011 through 2016.

Over-the-counter (OTC) drugs, nutritional drugs, and drug delivery products are discussed in a separate section of this report.

REASONS FOR DOING THIS STUDY

The majority of pharmaceutical companies are now using contract manufacturing, research, and packaging services. To save costs and product development time while simultaneously being effective, efficient, and productive, pharmaceutical companies are relying on contract manufacturers to fulfill many basic as well as specialized competencies. This study discusses the different types of contracting companies, their roles, and the share of the market they claim. New developments and new technologies warrant the issuing of this report, which is an important resource for anyone analyzing the discussed markets.

Trends in outsourcing and new emerging markets for outsourcing are providing a new look to the market and greater options to pharmaceutical companies. The industry is seeing an increase in outsourcing as contract manufacturers, researchers, and packagers provide cheaper options as well as region-specific suppliers. The new state-of-the-art packaging facilities as well as expensive research facilities and capabilities of research organizations are enhancing the overall growth of the contract manufacturing industry. Contract manufacturers are providing pharmaceutical companies with expertise in all forms that the companies do not have available in-house.

INTENDED AUDIENCE

This study examines the areas of market growth in pharmaceuticals contract manufacturing, research, and packaging from the point of view of manufacturers and users. Strategic decision makers at biochemical and biotechnology companies, physicians, pharmaceuticals and biopharmaceuticals companies, and related research companies will find value in this study.

SCOPE OF THE STUDY

The scope of this study encompasses the contract manufacturing, research, and packaging markets. BCC analyzes each market and its applications for contract manufacturing by its need for outsourcing, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with various analytical, chemical, pharmaceutical, and contracting experts. Market sizing estimates and projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of pharmaceuticals through contract manufacturing and research. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, and consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

CHAPTER ONE: INTRODUCTION 1

STUDY OBJECTIVE 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 2

SCOPE OF THE STUDY 2

METHODOLOGY 2

INFORMATION SOURCES 3

ABOUT THE AUTHOR 3

RELATED BCC RESEARCH REPORTS 3

BCC ONLINE SERVICES 4

DISCLAIMER 4

CHAPTER TWO: SUMMARY 5

SUMMARY 5

SUMMARY (CONTINUED) 6

SUMMARY TABLE GLOBAL PHARMACEUTICAL CONTRACT

MANUFACTURING AND CONTRACT RESEARCH

ORGANIZATIONS REVENUE, THROUGH 2016 ($ BILLIONS) 7

SUMMARY FIGURE GLOBAL PHARMACEUTICAL CONTRACT

MANUFACTURING AND CONTRACT RESEARCH

ORGANIZATIONS REVENUE, 2009-2016 ($ BILLIONS) 7

CHAPTER THREE: OVERVIEW 8

DEFINITIONS 8

DEFINITIONS (CONTINUED) 9

HISTORY OF OUTSOURCING 10

TABLE 1 KEY DEVELOPMENTS IN THE HISTORY OF

OUTSOURCING 10

TABLE 1 (CONTINUED) 11

CHAPTER FOUR: OVERVIEW OF CONTRACT MANUFACTURING 12

TYPES OF CONTRACT MANUFACTURERS 12

CONTRACT MANUFACTURING TRAITS 12

REQUIREMENT 12

ABILITY TO BE FLEXIBLE 13

CAPABILITIES WITHOUT COST 13

ADVANTAGES AND DISADVANTAGES OF CONTRACT

MANUFACTURING 13

TABLE 2 KEY ADVANTAGES OF CONTRACT MANUFACTURING 14

TABLE 3 KEY DISADVANTAGES OF CONTRACT MANUFACTURING 14

SELECTING A CONTRACT MANUFACTURER 14

TABLE 4 KEY FACTORS IN SELECTING A CONTRACT

MANUFACTURER 15

TABLE 4 (CONTINUED) 16

ADDITIONAL FACTS ABOUT CONTRACT MANUFACTURING 16

LOCATION AND PROXIMITY 16

AFTER-SALES SUPPORT 16

CHAPTER FIVE: OVERVIEW OF CONTRACT RESEARCH 17

OVERVIEW OF CONTRACT RESEARCH 17

SERVICES OFFERED BY CONTRACT RESEARCH

ORGANIZATIONS 18

TABLE 5 SERVICES OF CONTRACT RESEARCH ORGANIZATIONS 18

TABLE 5 (CONTINUED) 19

SELECTING A CONTRACT RESEARCH ORGANIZATION 19

TABLE 6 KEY CHARACTERISTICS IN SELECTING A CONTRACT

RESEARCH ORGANIZATION 19

TABLE 6 (CONTINUED) 20

RESEARCH PROVIDED BY CONTRACT RESEARCH

ORGANIZATIONS 20

TABLE 7 TYPES OF RESEARCH PROVIDED BY CONTRACT

RESEARCH ORGANIZATIONS 20

TABLE 7 (CONTINUED) 21

CHAPTER SIX: OVERVIEW OF CONTRACT PACKAGING 22

NEEDING A CONTRACT PACKAGER 22

TABLE 8 REASONS BEHIND NEEDING A CONTRACT PACKAGER 22

TABLE 8 (CONTINUED) 23

SELECTING A CONTRACT PACKAGER 23

TABLE 9 KEY CHARACTERISTICS IN SELECTING A CONTRACT

PACKAGER 24

HIRING A CONTRACT PACKAGER 24

TABLE 10 KEY STEPS IN HIRING A CONTRACT PACKAGER 25

TYPES OF PACKAGING 25

TYPES OF PACKAGING (CONTINUED) 26

CHAPTER SEVEN: PROJECT MANAGEMENT 27

SPECIFICATIONS OF PROJECT MANAGEMENT 27

TABLE 11 STEPS OF PROJECT MANAGEMENT 27

TABLE 11 (CONTINUED) 28

PROCESSES OF PROJECT MANAGEMENT 28

TABLE 12 PROCESSES OF PROJECT MANAGEMENT 28

TABLE 12 (CONTINUED) 29

FACTORS INVOLVED 29

ROLE OF THE PROJECT MANAGER 29

TABLE 13 KEY RESPONSIBILITIES OF PROJECT MANAGERS 30

TECHNOLOGY TRANSFER 30

TABLE 14 TECHNOLOGY TRANSFER STEPS 31

CHAPTER EIGHT: REGULATORY ASPECTS 32

REGULATORY ASPECTS 32

TABLE 15 REGULATED FACTORS OF CMO'S AND CRO'S 33

TABLE 16 TITLE 21 CFR RULES ASSOCIATED WITH CONTRACT

MANUFACTURING 33

TABLE 16 (CONTINUED) 34

TABLE 16 (CONTINUED) 35

WARNING LETTERS 36

TABLE 17 WARNING LETTERS ISSUED TO CONTRACT

MANUFACTURERS, 2010 36

TABLE 18 WARNING LETTERS ISSUED TO CONTRACT

MANUFACTURERS, 2009 37

REGULATORY APPROVALS 37

TABLE 19 REGULATORY APPROVALS OF CONTRACT

MANUFACTURERS AND FACILITIES, JANUARY THROUGH

MARCH, 2011 38

TABLE 20 REGULATORY APPROVALS OF CONTRACT

MANUFACTURERS AND FACILITIES, 2010 38

TABLE 20 (CONTINUED) 39

TABLE 21 REGULATORY APPROVALS OF CONTRACT

MANUFACTURERS AND FACILITIES, 2009 39

TABLE 21 (CONTINUED) 40

CHAPTER NINE: INDUSTRY STRUCTURE FOR NORTH AMERICA 41

MARKET SHARE OF INDUSTRY LEADERS 41

CONTRACT MANUFACTURERS OF BULK DRUGS AND API'S 41

TABLE 22 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING BULK DRUGS/API'S, IN NORTH

AMERICA, 2010 (%) 41

TABLE 22 (CONTINUED) 42

FIGURE 1 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING BULK DRUGS/API'S, IN NORTH

AMERICA, 2010 (%) 42

CONTRACT MANUFACTURERS OF SOLID-DOSAGE FORMS 42

TABLE 23 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING SOLID DOSAGE FORMS, IN NORTH

AMERICA, 2010 (%) 43

FIGURE 2 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING SOLID DOSAGE FORMS, IN NORTH

AMERICA, 2010 (%) 43

CONTRACT MANUFACTURERS OF LIQUID DOSAGE FORMS 44

NONSTERILE 44

TABLE 24 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING NONSTERILE LIQUID DOSAGE FORMS,

IN NORTH AMERICA, 2010 (%) 44

FIGURE 3 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING NONSTERILE LIQUID DOSAGE FORMS,

IN NORTH AMERICA, 2010 (%) 45

STERILE 45

TABLE 25 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING STERILE LIQUID DOSAGE FORMS, IN

NORTH AMERICA, 2010 (%) 46

FIGURE 4 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING STERILE LIQUID DOSAGE FORMS, IN

NORTH AMERICA, 2010 (%) 46

CONTRACT MANUFACTURERS OF SEMISOLID DOSAGE FORMS 46

TABLE 26 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING SEMISOLID DOSAGE FORMS, IN

NORTH AMERICA, 2010 (%) 47

FIGURE 5 MARKET SHARE OF CONTRACT MANUFACTURING

COMPANIES PROVIDING SEMISOLID DOSAGE FORMS, IN

NORTH AMERICA, 2010 (%) 47

CONTRACT RESEARCH COMPANIES 48

TABLE 27 MARKET SHARE OF CONTRACT RESEARCH

COMPANIES, IN NORTH AMERICA, 2010 (%) 48

FIGURE 6 MARKET SHARE OF CONTRACT RESEARCH

COMPANIES, IN NORTH AMERICA, 2010 (%) 49

CONTRACT PACKAGING COMPANIES 49

TABLE 28 MARKET SHARE OF CONTRACT PACKAGING

COMPANIES, IN NORTH AMERICA 2010 (%) 50

FIGURE 7 MARKET SHARE OF CONTRACT PACKAGING

COMPANIES, IN NORTH AMERICA, 2010 (%) 50

CHAPTER TEN: TECHNOLOGY TRANSFER 51

REASONS FOR TECHNOLOGY TRANSFER 51

CHALLENGING PROBLEMS DURING TECHNOLOGY TRANSFER 52

TECHNOLOGY TRANSFER 53

STEPS FOR SUCCESSFUL TECHNOLOGY TRANSFER 53

TYPES OF CONTRACTUAL AGREEMENTS USED IN

TECHNOLOGY TRANSFER 54

CONFIDENTIAL DISCLOSURE AGREEMENT (CDA) 55

MATERIAL TRANSFER AGREEMENT (MTA) 55

ASSIGNMENT DEED 55

LICENSE AGREEMENT 56

CO-DEVELOPMENT AND CO-MARKETING AGREEMENTS 56

CHARACTERISTICS OF A SUCCESSFUL PROJECT 56

CHARACTERISTICS OF A SUCCESSFUL … (CONTINUED) 57

CHAPTER ELEVEN: NEW DEVELOPMENTS 58

LONZA 58

ABBOTT 59

HOSPIRA 60

COVIDIEN 60

OTHER 61

OTHER (CONTINUED) 62

CHAPTER TWELVE: MARKET ANALYSIS FOR NORTH AMERICA 63

CONTRACT MANUFACTURING 63

CONTRACT MANUFACTURE OF BULK DRUGS/API'S 63

Market Overview 63

Market Revenue 64

TABLE 29 BULK DRUG/API CONTRACT MANUFACTURING, FOR

NORTH AMERICA, THROUGH 2016 ($ BILLIONS) 65

FIGURE 8 BULK DRUG/API CONTRACT MANUFACTURING, FOR

NORTH AMERICA, 2009-2016 ($ BILLIONS) 65

CONTRACT MANUFACTURE OF DOSAGE FORMULATIONS 65

Solid Dosage Formulations 66

Market Overview 66

Market Revenue 67

TABLE 30 SOLID DOSAGE FORM CONTRACT MANUFACTURING,

FOR NORTH AMERICA, THROUGH 2016 ($ BILLIONS) 68

FIGURE 9 SOLID DOSAGE FORM CONTRACT MANUFACTURING,

FOR NORTH AMERICA, 2009-2016 ($ BILLIONS) 68

Market by Formulation 68

Market Revenue 69

TABLE 31 SOLID DOSAGE FORM CONTRACT MANUFACTURING

REVENUE, BY FORMULATION, FOR NORTH AMERICA,

THROUGH 2016 ($ BILLIONS) 69

FIGURE 10 SOLID DOSAGE FORM CONTRACT MANUFACTURING

REVENUE, BY FORMULATIONS, FOR NORTH AMERICA, 2009-

2016 ($ BILLIONS) 70

TABLE 32 SOLID DOSAGE FORM CONTRACT MANUFACTURING

MARKET SHARES, BY FORMULATION, FOR NORTH AMERICA,

2010 (%) 70

FIGURE 11 SOLID DOSAGE FORM CONTRACT MANUFACTURING

MARKET SHARES, BY FORMULATIONS, FOR NORTH AMERICA,

2010 (%) 71

Liquid Dosage Formulation 71

Market Overview 71

Market Revenue 72

Nonsterile Formulations 72

TABLE 33 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT

MANUFACTURING, FOR NORTH AMERICA, THROUGH 2016 ($

MILLIONS) 73

FIGURE 12 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT

MANUFACTURING, FOR NORTH AMERICA, 2009-2016 ($

MILLIONS) 73

Sterile Formulations 73

TABLE 34 LIQUID DOSAGE FORM (STERILE) CONTRACT

MANUFACTURING, FOR NORTH AMERICA, THROUGH 2016 ($

MILLIONS) 74

FIGURE 13 LIQUID DOSAGE FORM (STERILE) CONTRACT

MANUFACTURING, FOR NORTH AMERICA, THROUGH 2016 ($

MILLIONS) 74

Market by Formulation 74

Nonsterile Formulations 74

TABLE 35 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT

MANUFACTURING REVENUE, BY FORMULATION, FOR NORTH

AMERICA, THROUGH 2016 ($ MILLIONS) 75

FIGURE 14 LIQUID DOSAGE FORM (NON STERILE) CONTRACT

MANUFACTURING REVENUE, BY FORMULATION, FOR NORTH

AMERICA, 2009-2016 ($ MILLIONS) 76

TABLE 36 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT

MANUFACTURING MARKET SHARES BY FORMULATION, FOR

NORTH AMERICA, 2010 (%) 76

FIGURE 15 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT

MANUFACTURING MARKET SHARES, BY FORMULATION, FOR

NORTH AMERICA, 2010 (%) 77

Sterile Formulations 77

TABLE 37 LIQUID DOSAGE FORM (STERILE) CONTRACT

MANUFACTURING REVENUE, BY FORMULATION, FOR NORTH

AMERICA, THROUGH 2016 ($ MILLIONS) 78

FIGURE 16 LIQUID DOSAGE FORM (STERILE) CONTRACT

MANUFACTURING REVENUE, BY FORMULATION, FOR NORTH

AMERICA, 2009-2016 ($ MILLIONS) 78

TABLE 38 LIQUID DOSAGE FORM (STERILE) CONTRACT

MANUFACTURING MARKET SHARE, BY FORMULATION, FOR

NORTH AMERICA, 2010 (%) 79

FIGURE 17 LIQUID DOSAGE FORM (STERILE) CONTRACT

MANUFACTURING MARKET SHARE, BY FORMULATION, FOR

NORTH AMERICA, 2010 (%) 79

CONTRACT MANUFACTURE OF SEMISOLID DOSAGE

FORMULATIONS 79

Market Overview 79

Market Revenue 80

TABLE 39 SEMISOLID DOSAGE FORM CONTRACT

MANUFACTURING, FOR NORTH AMERICA, THROUGH 2016 ($

MILLIONS) 80

FIGURE 18 SEMISOLID DOSAGE FORM CONTRACT

MANUFACTURING, FOR NORTH AMERICA, 2009-2016 ($

MILLIONS) 81

TABLE 40 SEMISOLID DOSAGE FORM CONTRACT

MANUFACTURING REVENUE, BY FORMULATION, FOR NORTH

AMERICA, THROUGH 2016 ($ MILLIONS) 82

FIGURE 19 SEMISOLID DOSAGE FORM CONTRACT

MANUFACTURING REVENUE, BY FORMULATION, FOR NORTH

AMERICA, 2009-2016 ($ MILLIONS) 82

TABLE 41 SEMISOLID DOSAGE FORM CONTRACT

MANUFACTURING MARKET SHARE, BY FORMULATION, FOR

NORTH AMERICA, 2010 (%) 83

FIGURE 20 SEMISOLID DOSAGE FORM CONTRACT

MANUFACTURING MARKET SHARE, BY FORMULATION, FOR

NORTH AMERICA, 2010 (%) 83

CONTRACT MANUFACTURE OF ADVANCED DRUG

DELIVERY PRODUCTS 83

Market Overview 84

TABLE 42 CONTRACTING COMPANIES PROVIDING DRUG DELIVERY

SYSTEMS 85

Market Revenue 86

TABLE 43 ADVANCED DRUG DELIVERY SYSTEMS REVENUE BY

CONTRACT MANUFACTURING, FOR NORTH AMERICA,

THROUGH 2016 ($ BILLIONS) 86

FIGURE 21 ADVANCED DRUG DELIVERY SYSTEMS REVENUE BY

CONTRACT MANUFACTURING, FOR NORTH AMERICA,

THROUGH 2016 ($ BILLIONS) 86

Market by Formulation 87

TABLE 44 ADVANCED DRUG DELIVERY SYSTEMS FOR NORTH

AMERICA, BY CONTRACT MANUFACTURING REVENUE, BY

FORMULATION, THROUGH 2016 ($ MILLIONS) 88

FIGURE 22 ADVANCED DRUG DELIVERY SYSTEMS FOR NORTH

AMERICA, BY CONTRACT MANUFACTURING REVENUE, BY

FORMULATIONS, 2009-2016 ($ MILLIONS) 88

Market Share 89

TABLE 45 ADVANCED DRUG DELIVERY SYSTEMS FOR NORTH

AMERICA, BY CONTRACT MANUFACTURING MARKET SHARE,

BY FORMULATION, 2010 (%) 89

FIGURE 23 ADVANCED DRUG DELIVERY SYSTEMS FOR NORTH

AMERICA, BY CONTRACT MANUFACTURING MARKET SHARE,

BY FORMULATIONS, 2010 (%) 90

CONTRACT MANUFACTURE OF OTC AND NUTRITIONAL

PRODUCTS 90

Market Overview 91

Market Revenue 92

TABLE 46 OTC AND NUTRITIONAL PRODUCT REVENUE FOR

NORTH AMERICA BY CONTRACT MANUFACTURING, THROUGH

2016 ($ BILLIONS) 92

FIGURE 24 OTC AND NUTRITIONAL PRODUCT REVENUE FOR

NORTH AMERICA BY CONTRACT MANUFACTURING, 2009-2016

($ BILLIONS) 92

Market by Formulation 93

TABLE 47 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT

MANUFACTURING REVENUE BY FORMULATION FOR NORTH

AMERICA, THROUGH 2016 ($ BILLIONS) 93

FIGURE 25 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT

MANUFACTURING REVENUE, BY FORMULATION, FOR NORTH

AMERICA, 2009-2016 ($ BILLIONS) 94

Market Shares 94

TABLE 48 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT

MANUFACTURING MARKET SHARE, BY FORMULATION, FOR

NORTH AMERICA, 2010 (%) 94

FIGURE 26 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT

MANUFACTURING MARKET SHARE, BY FORMULATIONS, FOR

NORTH AMERICA, 2010 (%) 95

CONTRACT RESEARCH 95

MARKET OVERVIEW 95

Partnerships 96

Expansions of Facilities 96

MARKET REVENUE 96

TABLE 49 CONTRACT RESEARCH REVENUE FOR NORTH

AMERICA, THROUGH 2016 ($ BILLIONS) 97

FIGURE 27 CONTRACT RESEARCH REVENUE, FOR NORTH

AMERICA, 2009-2016 ($ BILLIONS) 97

Market by Discipline 97

TABLE 50 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR

NORTH AMERICA, THROUGH 2016 ($ BILLIONS) 98

FIGURE 28 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR

NORTH AMERICA, 2009-2016 ($ BILLIONS) 98

Market Shares by Discipline 99

TABLE 51 CONTRACT RESEARCH MARKET SHARE, BY

DISCIPLINE, FOR NORTH AMERICA, 2010 (%) 99

FIGURE 29 CONTRACT RESEARCH MARKET SHARE, BY

DISCIPLINE, FOR NORTH AMERICA, 2010 (%) 99

CONTRACT PACKAGING 100

MARKET OVERVIEW 100

Market Revenue 100

TABLE 52 CONTRACT PACKAGING REVENUE, FOR NORTH

AMERICA, THROUGH 2016 ($ BILLIONS) 101

FIGURE 30 CONTRACT PACKAGING REVENUE, FOR NORTH

AMERICA, 2009-2016 ($ BILLIONS) 101

Market by Package Type 102

TABLE 53 CONTRACT PACKAGING REVENUE BY TYPE, FOR

NORTH AMERICA, THROUGH 2016 ($ MILLIONS) 103

FIGURE 45 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR

NORTH AMERICA, 2009-2016 ($ MILLIONS) 103

Market Share by Type 104

TABLE 54 CONTRACT PACKAGING MARKET SHARE, BY TYPE, FOR

NORTH AMERICA, 2010 (%) 104

FIGURE 31 CONTRACT PACKAGING MARKET SHARE, BY TYPE,

FOR NORTH AMERICA, 2010 (%) 104

CHAPTER THIRTEEN: MARKET SHARE BY REGION 105

MARKET SHARE OF CONTRACT MANUFACTURED API'S 105

TABLE 55 BULK DRUG/API CONTRACT MANUFACTURING

MARKET SHARE, BY REGION, 2010 (%) 105

FIGURE 32 BULK DRUG/API CONTRACT MANUFACTURING

MARKET SHARE, BY REGION, 2010 (%) 106

MARKET SHARE OF CONTRACT MANUFACTURED SOLID

DOSAGE FORMS 106

TABLE 56 SOLID DOSAGE FORM CONTRACT MANUFACTURING

MARKET SHARE, BY REGION, 2010 (%) 106

FIGURE 33 SOLID DOSAGE FORM CONTRACT MANUFACTURING

MARKET SHARE, BY REGION, 2010 (%) 107

MARKET SHARE OF CONTRACT MANUFACTURED LIQUID

DOSAGE FORMULATIONS 107

NONSTERILE FORMULATIONS 107

TABLE 57 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT

MANUFACTURING MARKET SHARE, BY REGION, 2010 (%) 107

FIGURE 34 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT

MANUFACTURING MARKET SHARE, BY REGION, 2010 (%) 108

STERILE FORMULATIONS 108

TABLE 58 LIQUID DOSAGE FORM (STERILE) CONTRACT

MANUFACTURING MARKET SHARE, BY REGION, 2010 (%) 108

FIGURE 35 LIQUID DOSAGE FORM (STERILE) CONTRACT

MANUFACTURING MARKET SHARE, BY REGION, 2010 (%) 109

MARKET SHARE OF CONTRACT MANUFACTURED SEMISOLID

DOSAGE FORMULATIONS 109

TABLE 59 SEMISOLID DOSAGE FORM CONTRACT

MANUFACTURING MARKET SHARES, BY REGION, 2010 (%) 109

FIGURE 36 SEMISOLID DOSAGE FORM CONTRACT

MANUFACTURING MARKET SHARE, BY REGION, 2010 (%) 110

MARKET SHARE OF CONTRACT MANUFACTURED ADVANCED

DRUG DELIVERY PRODUCTS 110

TABLE 60 DRUG DELIVERY CONTRACT MANUFACTURING

MARKET SHARE, BY REGION, 2010 (%) 110

FIGURE 37 DRUG DELIVERY CONTRACT MANUFACTURING

MARKET SHARE, BY REGION, 2010 (%) 111

MARKET SHARE OF CONTRACT MANUFACTURED OTC AND

NUTRITIONAL PRODUCTS 111

TABLE 61 OTC AND NUTRITIONAL PRODUCTS CONTRACT

MANUFACTURING MARKET SHARE, BY REGION, 2010 (%) 111

FIGURE 38 OTC AND NUTRITIONAL PRODUCT CONTRACT

MANUFACTURING MARKET SHARE, BY REGION, 2010 (%) 112

MARKET SHARE OF CONTRACT RESEARCH 112

TABLE 62 CONTRACT RESEARCH MARKET SHARE, BY REGION,

2010 (%) 112

FIGURE 39 CONTRACT RESEARCH MARKET SHARE, BY REGION,

2010 (%) 113

MARKET SHARE OF CONTRACT PACKAGING 113

TABLE 63 CONTRACT PACKAGING MARKET SHARE, BY REGION,

2010 (%) 113

FIGURE 40 CONTRACT PACKAGING MARKET SHARE, BY REGION,

2010 (%) 114

CHAPTER FOURTEEN: CONTRACT MANUFACTURING APPLICATIONS

FOR NORTH AMERICAN MARKETS 115

CARDIOVASCULAR DRUGS 115

MARKET REVENUE 116

TABLE 64 REVENUE FROM CONTRACT MANUFACTURERS OF

CARDIOVASCULAR DRUGS, IN NORTH AMERICA, THROUGH

2016 ($ MILLIONS) 117

FIGURE 41 REVENUE FROM CONTRACT MANUFACTURERS OF

CARDIOVASCULAR DRUGS, IN NORTH AMERICA, 2009-2016 ($

MILLIONS) 117

REPRODUCTIVE DRUG MARKET 117

REPRODUCTIVE DRUG MARKET (CONTINUED) 118

MARKET REVENUE 119

TABLE 65 REVENUE FROM CONTRACT MANUFACTURERS OF

REPRODUCTIVE DRUGS, IN NORTH AMERICA, THROUGH 2016

($ MILLIONS) 119

FIGURE 42 REVENUE FROM CONTRACT MANUFACTURERS OF

REPRODUCTIVE DRUGS, IN NORTH AMERICA, 2009-2016 ($

MILLIONS) 119

ONCOLOGY DRUG MARKET 120

MARKET REVENUE 121

TABLE 66 REVENUE FROM CONTRACT MANUFACTURERS OF

ONCOLOGY DRUGS, IN NORTH AMERICA, THROUGH 2016 ($

MILLIONS) 121

FIGURE 43 REVENUE FROM CONTRACT MANUFACTURERS OF

ONCOLOGY DRUGS, IN NORTH AMERICA, 2009-2016 ($

MILLIONS) 122

ANALGESICS MARKET 122

MARKET REVENUE 123

TABLE 67 REVENUE FROM CONTRACT MANUFACTURERS OF

ANALGESICS, IN NORTH AMERICA, THROUGH 2016 ($

MILLIONS) 123

FIGURE 44 REVENUE FROM CONTRACT MANUFACTURERS OF

ANALGESICS, IN NORTH AMERICA, 2009-2016 ($ MILLIONS) 124

MARKET REVENUE 125

TABLE 68 REVENUE FROM CONTRACT MANUFACTURERS OF

ANTIVIRALS, IN NORTH AMERICA, THROUGH 2016 ($

MILLIONS) 125

FIGURE 45 REVENUE FROM CONTRACT MANUFACTURERS OF

ANTIVIRALS, IN NORTH AMERICA, 2009-2016 ($ MILLIONS) 126

ANTIBIOTICS MARKET 126

MARKET REVENUE 127

TABLE 69 REVENUE FROM CONTRACT MANUFACTURERS OF

ANTIBIOTICS, IN NORTH AMERICA, THROUGH 2016 ($

MILLIONS) 127

FIGURE 46 REVENUE FROM CONTRACT MANUFACTURERS OF

ANTIBIOTICS, IN NORTH AMERICA, 2009-2016 ($ MILLIONS) 128

MARKETS FOR OTHER DRUGS 128

MARKET REVENUE 129

TABLE 70 REVENUE FROM CONTRACT MANUFACTURERS OF

OTHER DRUGS, IN NORTH AMERICA, THROUGH 2016 ($

BILLIONS) 129

FIGURE 47 REVENUE FROM CONTRACT MANUFACTURERS OF

OTHER DRUGS, IN NORTH AMERICA, 2009-2016 ($ BILLIONS) 130

CHAPTER FIFTEEN: PATENT ANALYSIS 131

PATENTS BY YEAR 131

TABLE 71 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, 2009-

2011 131

FIGURE 62 NUMBER OF PATENTS, BY YEAR, 2009-MAY 31, 2011 131

FIGURE 63 NUMBER OF PATENTS, BY YEAR, 2009-MAY 31, 2011 (%) 132

PATENTS BY COMPANY 132

TABLE 72 NUMBER OF US PATENTS, BY COMPANY, 2009-2011 133

FIGURE 64 NUMBER OF US PATENTS, BY COMPANY, 2009-2011 134

PATENTS BY COUNTRY 135

TABLE 73 NUMBER OF US PATENTS, BY COUNTRY, 1/1/2009 TO

5/31/2011 135

FIGURE 65 NUMBER OF US PATENTS, BY COUNTRY, 1/1/2009 TO

5/31/2011 136

TABLE 74 PATENT SHARES, BY COUNTRY, 1/1/2009 TO 5/31/2011

(%) 136

FIGURE 66 PATENT SHARES, BY COUNTRY, 1/1/2009 TO

5/31/2011 (%) 137

PATENTS BY EMPHASIS 137

TABLE 75 PATENTS, BY EMPHASIS, 1/1/2009 TO 5/31/2011 138

FIGURE 67 NUMBER OF US PATENTS, BY EMPHASIS, 1/1/2009 TO

5/31/2011 138

CHAPTER SIXTEEN: CURRENT ENVIRONMENT 139

SITUATION OF THE NORTH AMERICAN CONTRACTING

MARKETS 139

CONTRACT MANUFACTURING OF API AND DOSAGE

FORMS 139

CONTRACT MANUFACTURING OF OTC AND

NUTRACEUTICALS 139

CONTRACT RESEARCH 140

CONTRACT PACKAGING 140

SITUATION OF THE EUROPEAN CONTRACTING MARKET 140

CONTRACT MANUFACTURING OF API AND DOSAGE

FORMS 140

CONTRACT MANUFACTURING OF OTC AND

NUTRACEUTICALS 140

CONTRACT RESEARCH 141

CONTRACT PACKAGING 141

SITUATION OF THE ROW CONTRACTING MARKET 141

CONTRACT MANUFACTURING OF API AND DOSAGE

FORMS 141

CONTRACT MANUFACTURING OF OTC AND

NUTRACEUTICALS 141

CONTRACT RESEARCH 142

CONTRACT PACKAGING 142

OPPORTUNITIES AND CHALLENGES OF THE CURRENT

CONTRACT MANUFACTURING INDUSTRY 142

OPPORTUNITIES AND CHALLENGES…(CONTINUED) 143

OPPORTUNITIES AND CHALLENGES…(CONTINUED) 144

CHAPTER SEVENTEEN: COMPANY PROFILES 145

AAI PHARMA, INC 145

ABBOTT LABORATORIES 145

AEROGEN LTD 146

ALKERMES 146

ALTHEA TECHNOLOGIES 147

AMCOR 148

AMERISOURCE BERGEN CORPORATION 148

AMPAC FINE CHEMICALS 149

ALBANY MOLECULAR RESEARCH INC (AMRI) 149

AP PHARMA INC 150

APTUIT INC 150

ARADIGM CORPORATION 151

BASF SE 152

BAXTER HEALTHCARE 152

BCM/BOOTS MANUFACTURING 153

BOEHRINGER INGELHEIM 154

BRISTOL-MYERS SQUIBB 154

CAMBREX CORPORATION 155

CANGENE CORPORATION 156

CATALENT PHARMA SOLUTIONS 156

CEDARBURG HAUSER PHARMACEUTICALS INC 157

CENEXI 157

CHARLES RIVER LABORATORIES 158

CHEMBRIDGE CORP 158

CLEARSTONE CENTRAL LABORATORIES 159

CONFAB LABORATORIES 159

COVANCE INC 160

COVIDIEN 160

CONTRACT PHARMACEUTICALS LIMITED 161

CORDEN PHARMA SWITZERLAND LLC 161

DAVOS PHARMA 162

DECODE GENETICS 162

DISHMAN PHARMACEUTICALS AND CHEMICALS LTD 163

DOW CHEMICAL 164

DPT LABORATORIES INC 164

DR REDDY'S LABORATORIES 165

DSM PHARMACEUTICAL PRODUCTS 165

FUJIFILM DIOSYNTH BIOTECHNOLOGY 166

ELAN DRUG TECHNOLOGIES 166

EVOTEC AG 167

FULCRUM PHARMA PLC 167

GIRINDUS AG 168

GLAXOSMITHKLINE 168

HOSPIRA 169

HAUPT PHARMA AG 170

HOVIONE SA 170

ICON PLC 171

INC RESEARCH, INC 171

JUBILANT LIFESCIENCES 172

KENDLE INTERNATIONAL INC 172

KP PHARMACEUTICAL TECHNOLOGIES INC 173

KV PHARMACEUTICAL CO 173

LIGAND PHARMACEUTICALS, INC 174

LONZA GROUP 174

LYNE LABORATORIES 175

MERCK / MSD BIOMANUFACTURING NETWORK 176

MIKART INC 176

NEXTPHARMA TECHNOLOGIES 177

NORWICH PHARMACEUTICALS 177

NOVAVAX, INC 178

OMNICARE CLINICAL RESEARCH 178

PAREXEL INTERNATIONAL CORPORATION 179

PATHEON INC 179

PERRIGO COMPANY 180

PFIZER (KING PHARMACEUTICALS 181

PIRAMAL HEALTHCARE LIMITED 181

PPD 182

PRA INTERNATIONAL 182

QUINTILES 183

RANBAXY 183

REGIS TECHNOLOGIES, INC 184

SKYEPHARMA 184

TALECRIS BIOTHERAPEUTICS INC 185

VETTER PHARMA INTERNATIONAL GMBH 185

WOCKHARDT LIMITED 186

WUXI APP TEC 187

XCELLEREX LLC 187

ZACH SYSTEM SPA 188

APPENDIX I: ABBREVIATIONS 189

To order this report:

Manufacturing Industry: Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on North America

Manufacturing Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Generic Drugs: The Global Market
2. Generic Drugs: The Global Market: Focus on the Americas
3. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on Europe
4. Prosthetic Heart Valves - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
5. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
6. Accuray Incorporated to Speak at UBS Global Life Sciences Conference
7. Unilife to Present at the 2011 UBS Global Life Sciences Conference in New York City
8. Aperion Biologics Invited to Present at the UBS Global Life Sciences Conference
9. Jazz Pharmaceuticals Announces Presentation at the UBS Global Life Sciences Conference in New York on September 20
10. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
11. ClinStar to Present on Russias Performance as an Emerging Market in Global Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Global Immunology Market to 2022 - ... market growth Summary Immune-mediated inflammatory diseases ... that affect 5–7% of western populations. Although they ... and key patient demographics, they are pathophysiologically linked, ... an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure ... to individuals in need. The event is scheduled to take place on February 27, ... to provide dental care to community members in need. Each patient will be given ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Ben Amini, ... it is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the ... oral health care, including general dentistry, cosmetic treatments, periodontics, implant dentistry , ...
(Date:2/5/2016)... Pekin, IL (PRWEB) , ... February 05, 2016 , ... ... in disguised form as a dream. A hallmark feature of patients with eating disorders ... and needs. The eating disorder behaviors and obsessions are regarded as maladaptive means for ...
(Date:2/5/2016)... ... February 05, 2016 , ... California Mobile ... the debut of their latest mobile kitchen model, featuring customizable stainless steel interiors ... high-volume commercial kitchens for use anywhere in the U.S. Many of their units ...
(Date:2/5/2016)... Russia (PRWEB) , ... February 05, 2016 , ... Calls ... has a completely new user interface design and the developer has fixed known bugs ... those they want to on their phone while not consuming any of their device’s ...
Breaking Medicine News(10 mins):